In vitro evaluation of nine antiviral compounds for their potential effect against equid herpesvirus-4 - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2021

In vitro evaluation of nine antiviral compounds for their potential effect against equid herpesvirus-4

Résumé

Background: Equid herpesvirus-4 (EHV-4) is a frequent respiratory pathogen of the horse. Occasional strains of EHV-4 sporadically induce abortion or neonatal death and although not clearly demonstrated, its involvement in neurological forms has been suggested. Despite prophylactic approaches using vaccines, resurgence of EHV-4 infection still constitutes an important threat to the horse industry. Yet very few studies have been conducted on the search for antiviral molecules against EHV-4 in vitro. Objectives: To assess the effectiveness of 9 antiviral compounds against EHV-4. Study design: In vitro experiment. Methods: Using Real-Time Cell Analysis (RTCA) of CCL26 cell line (African green monkey kidney) infected with EHV-4, 9 compounds with antiviral properties against EHV-1 were screened. CCL26 cells were infected with EHV-4 405/76 reference strain (VR2230) at a MOI 0.24 in the presence of 8 concentrations (50 to 0.39 μM) of each selected compound: aciclovir, ganciclovir, valganciclovir, decitabine, idoxuridine, pritelivir, cidofovir, aphidicolin and vidarabine. Formation of cytopathic effects was monitored by RTCA (xCELLigence and Incucyte®) and the viral load was quantified by qPCR. EC50 values for both xCELLigence and qPCR methods were determined. Results: EC50 values showed that seven molecules have an antiviral potency to prevent infection of CCL26 with EHV-4 in vitro. Aphidicolin was the most potent compound with an EC50 value of 1.63±0.76 μM measured by xCELLigence and 0.25±0.12 μM when measured by qPCR. Nucleoside analogs aciclovir and vidarabine were not efficient in preventing infection of CCL26 with EHV-4. Main limitation: Results need to be confirmed on different equine cell lines and with different EHV-4 strains isolated from the field. Conclusions: Seven antiviral compounds (ganciclovir, valganciclovir, decitabine, idoxuridine, pritelivir, cidofovir and aphidicolin) prevent EHV-4 cytopathic effect in CCL26 cells in vitro. Aciclovir, the most widely used antiviral in vivo against alpha-herpesviruses, does not appear to be effective against EHV-4 in vitro.

Mots clés

Dates et versions

hal-03385399 , version 1 (27-10-2021)

Identifiants

Citer

Camille Normand, Christine Fortier, Côme Thieulent, Christel Marcillaud-Pitel, Stéphane Pronost, et al.. In vitro evaluation of nine antiviral compounds for their potential effect against equid herpesvirus-4. 11th International Equine Infectious Diseases Conference, Sep 2021, Online, France. pp.60, ⟨10.1111/evj.89_13495⟩. ⟨hal-03385399⟩
59 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More